Seres is a biotech company researching on microbiome therapeutics.
Market cap around 300M
Volume 2.43M
You might have heard a few years ago, there was work being done on fecal transplants to heal Clostridium Difficile infections.
Well, they were finally able to make microbiome spores into a pill (VOWST) making the treatment for recurring C.diff much more available.
VOWST has been FDA approved in april 2023, yet Seres stock is going down.
It's the first and only medication out there for such recurring infections, the sells have started, it seems well received by the medical community and they have a partership with Nestle (with rumors of buy out).
Why is it still valued as a research company now that they have an FDA approved revolutionary medication on the market, and why is it dropping?
The stock is highly shorted: 15.78% of float, 29.90% of share outstanding
Market manipulation going on you think?
What's your opinion on this?
I know meds can be taken out after FDA approval, so there's still a risk, but it seems to me that it's LESS risky than before the approval and it should have gone up not down.
I don't know much about market manipulation, can it sink it to bankruptcy?
(and why would anyone do that?)
Leave a Reply